Delving into the Latest Updates on Suzhou Dixinchenke Biotechnology Co., Ltd. with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Toxin

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Toxin	1

Top 5 Target	Count

SNAP25(Synaptosomal-associated protein 25)	1

I期：主要目的：评价DN001重组A型肉毒毒素治疗中、重度眉间纹的安全性和耐受性次要目的：评价DN001治疗中、重度眉间纹的免疫原性；初步评价DN001治疗中、重度眉间纹的有效性；探索性目的：初步评价DN001治疗中、重度眉间纹的其他有效性 II期：主要目的：评价DN001治疗中、重度眉间纹的有效性和安全性次要目的：评价DN001治疗中、重度眉间纹的其他有效性；评价DN001治疗中、重度眉间纹的其他安全性；评价DN001治疗中、重度眉间纹的免疫原性探索性目的：评价DN001治疗中、重度眉间纹的其他有效性

[Translation]

Phase I: Primary purpose: To evaluate the safety and tolerability of DN001 recombinant botulinum toxin type A in the treatment of moderate and severe glabellar lines Secondary purpose: To evaluate the immunogenicity of DN001 in the treatment of moderate and severe glabellar lines; To preliminarily evaluate the effectiveness of DN001 in the treatment of moderate and severe glabellar lines; Exploratory purpose: To preliminarily evaluate the other effectiveness of DN001 in the treatment of moderate and severe glabellar lines Phase II: Primary purpose: To evaluate the effectiveness and safety of DN001 in the treatment of moderate and severe glabellar lines Secondary purpose: To evaluate the other effectiveness of DN001 in the treatment of moderate and severe glabellar lines; To evaluate the other safety of DN001 in the treatment of moderate and severe glabellar lines; To evaluate the immunogenicity of DN001 in the treatment of moderate and severe glabellar lines Exploratory purpose: To evaluate the other effectiveness of DN001 in the treatment of moderate and severe glabellar lines

Start Date14 Sep 2024

Sponsor / Collaborator

Suzhou Dixinchenke Biotechnology Co., Ltd.

100 Clinical Results associated with Suzhou Dixinchenke Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Suzhou Dixinchenke Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Suzhou Dixinchenke Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Suzhou Dixinchenke Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data